Table 3. Comparison of Risks of New-Onset Diagnoses First Prescriptions, Associated With COVID-19 and SARI Admissions.
| Outcomea | Maximally adjusted hazard ratio (95% CI) |
|---|---|
| New-onset anxiety diagnosis | |
| Acute myocardial infarction | 1 [Reference] |
| SARI | 0.66 (0.49-0.88) |
| COVID-19 | 0.62 (0.46-0.83) |
| New-onset dementia diagnosis | |
| Acute myocardial infarction | 1 [Reference] |
| SARI | 2.24 (1.53-3.27) |
| COVID-19 | 1.92 (1.28-2.87) |
| New-onset depression diagnosis | |
| Acute myocardial infarction | 1 [Reference] |
| SARI | 1.16 (0.48-2.81) |
| COVID-19 | 0.68 (0.23-2.07) |
| New antidepressant prescription | |
| Acute myocardial infarction | 1 [Reference] |
| SARI | 1.46 (1.16-1.85) |
| COVID-19 | 1.55 (1.24-1.94) |
| New hypnotic/anxiolytic prescription | |
| Acute myocardial infarction | 1 [Reference] |
| SARI | 1.09 (0.88-1.35) |
| COVID-19 | 1.04 (0.83-1.28) |
| New antipsychotic prescription | |
| Acute myocardial infarction | 1 [Reference] |
| SARI | 2.48 (1.96-3.15) |
| COVID-19 | 2.00 (1.58-2.54) |
Abbreviation: SARI, severe acute respiratory infections.
a
These are compared with the risks seen in survivors of hospitalization for acute myocardial infarction during the study period (reference group; January 24, 2020, to July 7, 2021).